MED vs SCI

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Oct 02, 2026

MED

50.0
AI Score
VS
SCI Wins

SCI

67.4
AI Score

Investment Advisor Scores

MED

50score
Recommendation
HOLD

SCI

67score
Recommendation
BUY

AI Analyst Insights

AI insights temporarily unavailable

Detailed Metrics Comparison

Metric MED SCI Winner
Revenue 152.43M 2.20B SCI
Net Income -5.22M 260.63M SCI
Gross Margin 69.0% 25.5% MED
Net Margin -3.4% 11.8% SCI
Operating Income -7.62M 475.40M SCI
ROE -2.7% 17.0% SCI
ROA -2.0% 1.4% SCI
Total Assets 260.40M 19.21B SCI
Cash 71.91M 260.41M SCI
Current Ratio 4.86 0.53 MED

Relative Price Performance (Last 90 Days)

MED 1M: -7.4% · 3M: +6.3% SCI 1M: -4.9% · 3M: -0.8%

Current Technical Phase

MED

Neutral
Hold

Mixed signals - no dominant trend phase, RSI 48

RSI (14): 47.9 · Price: $11.73

SCI

Neutral
Hold

Mixed signals - no dominant trend phase, RSI 38

RSI (14): 38.4 · Price: $77.14

Fundamentals Snapshot

Metric MED SCI
Market Cap — —
Forward P/E -41.9 16.8
Trailing P/E — 19.9
Revenue (TTM) — —
Revenue Growth -0.3% 0.0%
Gross Margin 0.7% 0.3%
Operating Margin -0.1% 0.2%
EPS -2.33 3.85
Dividend Yield — 0.02%

Frequently Asked Questions

Based on our detailed analysis, SCI is currently the stronger investment candidate, winning 8 of the key financial metrics based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.